

November 23, 2021



Malaria
Vaccine
Project

Your support of the Malaria Vaccine Project

On behalf of the Malaria Vaccine Project Committee, I wish to express my sincere thanks to all supporters for your very generous and ongoing support of this Project. With your help, we have now raised over \$1.33 million—an incredible effort. Rotary clubs, districts, friends and special supporters like you throughout Australia and overseas have raised more than \$700,000 of this total and we are very appreciative of a grant of \$500,000 from the Federal Government Department of Health. We especially appreciate your help during the continuing struggle with COVID 19. I have provided below a brief summary of the Malaria Vaccine Project and an indication of where the malaria research is headed

PATRONS

Hon Lawrence Springborg
PRID Noel Trevaskis OAM
PRIP Glen W Kinross AO

The Malaria Vaccine Project (MVP):

This is a joint project between Rotary District 9640 and the Institute for Glycomics at Griffith University. The project was launched in March 2017 by then Governor-General, His Excellency General Sir Peter Cosgrove AK, CVO, MC. The project is designed to support the development of a promising malaria vaccine PlasProtect[®] created by Professor Michael Good AO. Professor Good was at one time Director of Berghofer QIMR and in 2010 was selected as a "Queensland Great". The Malaria Vaccine Project is registered with Rotary Australia Benevolent Society (RABS) which enables it to receive DGR1 status. The Project's goal is to raise \$2.5 million to enable the vaccine to proceed to Clinical trials in an endemic country like PNG or Uganda.

WEBSITE/Facebook: Google- malariavaccineproject.com

2. The Malaria Vaccine Research.

PlasProtect[®] is a whole parasite vaccine that is chemically treated to make it safe and effective in fighting the several strains of the malaria parasite. During the last two years, Professor Good and his team have successfully carried out Phase 1(a) Clinical trials where human subjects were given the vaccine, *housed in a human blood cell*, and were then challenged with a malaria parasite. The sample was small, but Professor Good commented that the trial went very well and "It is the first time a whole-parasite vaccine has protected multiple individuals from the blood forms of a malaria infection." Very exciting news!!

The vaccine is quite challenging to preserve and the researchers are now putting their efforts into a "lipid" vaccine that can be freeze-dried, stored and transported. This "lipid" form of PlasProtect[®] has already undergone very successful animal studies and in 2022 a formal toxicological analysis will be completed in the USA. It will then proceed to further Phase 1(b) clinical trials that will assess safety and ability to activate an immune response, prior to testing the efficacy of the vaccine in a malaria endemic country. If PlasProtect[®] continues to perform well a critical trial in an endemic country may not be that far away.

Our goal is to raise sufficient funds to make that happen--in essence to start saving the lives of those 400,000 children who die from malaria every year. Thank you again for your beautiful gifts to this work and please continue to help us to reach our *\$2.5 million goal*. WE ARE ALREADY HALF-WAY THERE and are hopeful that the corporate sector will join Rotary and Governments to make this possible.

PDG Graham Jones AM, Chairman Malaria Vaccine Project Committee

PO Box 84, Southport
Queensland 4215
e. graham.a.g.jones@gmail.com
p. +61 406040038
www.malariavaccineproject.com

